臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
臺大學術典藏 |
2022-08-19T00:20:36Z |
Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014)
|
Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K. |
臺大學術典藏 |
2022-08-19T00:20:35Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.; CHIUN HSU; Chan S.L.; Choo S.-P.; Kudo M. |
臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
臺大學術典藏 |
2022-08-10T02:37:40Z |
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
|
Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG; Garassino M.C. |
臺大學術典藏 |
2022-08-10T02:37:38Z |
Female leadership in oncology�Xhas progress stalled? Data from the ESMO W4O authorship and monitoring studies
|
Berghoff A.S.; Sessa C.; CHIH-HSIN YANG; Tsourti Z.; Tsang J.; Tabernero J.; Peters S.; Linardou H.; Letsch A.; Haanen J.; Garralda E.; Garassino M.C.; Furness A.J.S.; Felip E.; Dimopoulou G.; Dafni U.; Choo S.P.; Banerjee S.; Bajpai J.; Adjei A.A.; Garrido P. |
臺大學術典藏 |
2022-06-10T06:10:59Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
臺大學術典藏 |
2021-08-31T06:29:17Z |
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
|
Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG |
臺大學術典藏 |
2021-08-11T03:46:38Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
臺大學術典藏 |
2021-01-28T01:06:21Z |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle M.;Lowery M.;Shroff R.T.;Weiss K.H.;Springfeld C.;Borad M.J.;Ramanathan R.K.;Goyal L.;Sadeghi S.;Macarulla T.;El-Khoueiry A.;Kelley R.K.;Borbath I.;Choo S.P.;Oh D.-Y.;Philip P.A.;Chen L.-T.;Reungwetwattana T.;Van Cutsem E.;Kun-Huei Yeh;Ciombor K.;Finn R.S.;Patel A.;Sen S.;Porter D.;Isaacs R.;Zhu A.X.;Abou-Alfa G.K.;Bekaii-Saab T.; Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. |
臺大學術典藏 |
2020-04-10T12:51:02Z |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L. |
臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
國立成功大學 |
2019 |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin, S.;Chan, S.L.;Sukeepaisarnjaroen, W.;Han, G.;Choo, S.P.;Sriuranpong, V.;Pan, H.;Yau, T.;Guo, Y.;Chen, M.;Ren, Z.;Xu, J.;Yen, C.-J.;Lin, Z.-Z.;Manenti, L.;Gu, Y.;Sun, Y.;Tiedt, R.;Hao, L.;Song, W.;Tanwandee, Tanwandee T. |
國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |